Compare · POCI vs SLNO
POCI vs SLNO
Side-by-side comparison of Precision Optics Corporation Inc. (POCI) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both POCI and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 58.2x POCI ($47.5M).
- Over the past year, POCI is down 11.9% and SLNO is down 39.2% - POCI leads by 27.3 points.
- SLNO has hit the wire 1 time in the past 4 weeks while POCI has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for POCI).
- Company
- Precision Optics Corporation Inc.
- Soleno Therapeutics Inc.
- Price
- $4.31-6.30%
- $53.02+0.08%
- Market cap
- $47.5M
- $2.76B
- 1M return
- -27.01%
- +0.76%
- 1Y return
- -11.86%
- -39.20%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 1
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest POCI
- Precision Optics to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
- Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
- Precision Optics Reports Third Quarter Fiscal Year 2026 Financial Results
- SEC Form 10-Q filed by Precision Optics Corporation Inc.
- New insider Needham Investment Management Llc claimed ownership of 3,341,100 shares (SEC Form 3)
- Precision Optics Schedules Third Quarter of Fiscal Year 2026 Conference Call for May 13, 2026
- Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program
- SEC Form 3 filed by new insider Needham Investment Management Llc
- SEC Form 4 filed by Coll Wayne M
- SEC Form 4 filed by Traut Joseph
Latest SLNO
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)